XFOR Stock Overview
A biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
X4 Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.21 |
| 52 Week High | US$1.39 |
| 52 Week Low | US$0.19 |
| Beta | 0.58 |
| 1 Month Change | -38.25% |
| 3 Month Change | -62.85% |
| 1 Year Change | -84.33% |
| 3 Year Change | -85.21% |
| 5 Year Change | -97.88% |
| Change since IPO | -98.62% |
Recent News & Updates
Recent updates
US Launch And EMA Approval Will Expand Global Reach
Mar 30 The transition to a commercial-stage pharmaceutical and strategic international partnerships could significantly boost revenue growth and international market presence.X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data
Jul 02Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?
Mar 26
Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?
Apr 19Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?
Oct 07X4 Pharmaceuticals: Upcoming Catalysts
Sep 19X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%
Jul 20X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended
Jul 01X4 Pharma: Late Stage Nanocap Targeting Rare Diseases
Aug 03Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?
Jun 22X4 Pharmaceuticals EPS misses by $0.44
May 06How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?
Mar 16Shareholder Returns
| XFOR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.1% | 0.5% | 5.4% |
| 1Y | -84.3% | -11.9% | 3.6% |
Return vs Industry: XFOR underperformed the US Biotechs industry which returned -12% over the past year.
Return vs Market: XFOR underperformed the US Market which returned 3.6% over the past year.
Price Volatility
| XFOR volatility | |
|---|---|
| XFOR Average Weekly Movement | 20.8% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: XFOR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: XFOR's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 143 | Paula Ragan | www.x4pharma.com |
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections.
X4 Pharmaceuticals, Inc. Fundamentals Summary
| XFOR fundamental statistics | |
|---|---|
| Market cap | US$36.47m |
| Earnings (TTM) | -US$37.45m |
| Revenue (TTM) | US$2.56m |
14.3x
P/S Ratio-1.0x
P/E RatioIs XFOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XFOR income statement (TTM) | |
|---|---|
| Revenue | US$2.56m |
| Cost of Revenue | US$797.00k |
| Gross Profit | US$1.76m |
| Other Expenses | US$39.21m |
| Earnings | -US$37.45m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 68.83% |
| Net Profit Margin | -1,464.61% |
| Debt/Equity Ratio | 340.5% |
How did XFOR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/13 15:00 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
X4 Pharmaceuticals, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leah Rush Cann | Brookline Capital Markets |
| Arlinda Lee | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |